Dabrafenib plus trametinib was subsequently evaluated in ROAR, which was an open-label, single-arm, phase 2 basket study that included a biliary tract cancer cohort consisting of 43 patients with BRAF V600E-mutated, advanced biliary tract cancer with progression on prior therapy [78]. This evidence concerns the gene BRAF and biliary tract cancer.